Background and Study Aims: Regular intake of nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce the occurrence of colorectal adenoma and carcinoma, possibly by inducing apoptosis and/or decreasing proliferation in colorectal epithelial cells. Mesalazine is widely used in the treatment of patients with inflammatory bowel disease, and well tolerated. We investigated its effect on apoptosis and proliferation of colorectal mucosa in 21 patients with sporadic polyps of the large bowel.
Patients and Methods: In total, 17 patients with sporadic colorectal polyps (≥ 5 mm) underwent polypectomy and biopsy of uninvolved mucosa before and after treatment with 1 g/d mesalazine for 1, 3, 7 or 14 days. Four additional patients served as untreated controls. Apoptotic index (AI) was measured by terminal deoxynucleotidyl transferase-mediated d-uridine triphosphate nick-end labeling (TUNEL) assay; proliferation index (PI) was measured by immunohistochemical examination with anti-Ki67 antibody.
Results: Al was significantly increased 1 and 3 days after initiation of treatment with mesalazine compared with controls (P = 0.0107 for the 1-day treatment group and P = 0.0142 for the 3-day treatment group), and seemed to remain largely unchanged after longer treatment duration. Proliferation appeared to be decreased by mesalazine in all treatment groups, while proliferation in controls did not change (P = 0.0107 for the 1-day treatment group and P = 0.0142 for the 3-day treatment group compared with controls.
Conclusions: Mesalazine significantly induces apoptosis and decreases proliferation in colorectal mucosa in patients with sporadic polyps of the large bowel. This may be clinically relevant in that it may lower the rate of polyp recurrence after polypectomy, thereby possibly contributing to the chemoprevention of sporadic colorectal carcinoma.
References
-
1
Parker S L, Tong T, Bolden S, Wingo P A.
Cancer Statistics, 1996.
CA Cancer J Clin.
1996;
46
5-27
-
2
Kune G, Kune S, Watson L.
Colorectal cancer risk, chronic illnesses, operations, and medications: case-control results from the Melbourne Colorectal Cancer Study.
Cancer Res.
1988;
48
4399-4404
-
3
Thun M J, Namboodiri M M, Heath C W .
Aspirin use and reduced risk of fatal colon cancer.
N Engl J Med.
1991;
325
1593-1596
-
4
Giovannucci E, Egan K M, Hunter D J, et al.
Aspirin and the risk of colorectal cancer in women.
N Engl J Med.
1995;
333
609-614
-
5
Smalley W, Ray W A, Daugherty J, Griffin M R.
Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study.
Arch Intern Med.
1999;
159
161-166
-
6
Rosenberg L, Louik C, Shapiro S.
Nonsteroidal anti-inflammatory drug use and reduced risk of large bowel carcinoma.
Cancer.
1998;
82
2326-2333
-
7
Jacoby R F, Marshall D J, Newton M A, et al.
Chemoprevention of spontaneous intestinal adenomas in the ApcMin mouse model by the nonsteroidal anti-inflammatory drug piroxicam.
Cancer Res.
1996;
56
710-714
-
8
Rao C V, Rivenson A, Simi B, et al.
Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent.
Cancer Res.
1995;
55
1464-1472
-
9
Ritland S R, Gendler S J.
Chemoprevention of intestinal adenomas in the ApcMin mouse by piroxicam: kinetics, strain effects and resistance to chemosuppression.
Carcinogenesis.
1999;
20
51-58
-
10
Mahmoud N N, Dannenberg A J, Mestre J, et al.
Aspirin prevents tumors in a murine model of familial adenomatous polyposis.
Surgery.
1998;
124
225-231
-
11
Labayle D, Fischer D, Vielh P, et al.
Sulindac causes regression of rectal polyps in familial adenomatous polyposis.
Gastroenterology.
1991;
101
635-639
-
12
Giardello F M, Hamilton S R, Krush A J, et al.
Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis.
N Engl J Med.
1993;
328
1313-1316
-
13
Matsuhashi N, Nakajima A, Fukushima Y, et al.
Effects of sulindac on sporadic colorectal adenomatous polyps.
Gut.
1997;
40
344-349
-
14
Wallace J L.
Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years.
Gastroenterology.
1997;
112
1000-1016
-
15
Henry D, Lim L L, Garcia Rodriguez L A, et al.
Variability in risk of gastrointestinal complications with individual nonsteroidal anti-inflammatory drugs: results of a collaborative meta-analysis.
BMJ.
1996;
312
1563-1566
-
16
Bjarnasson I, Hayllar J, MacPherson A J, Russell A S.
Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans.
Gastroenterology.
1993;
104
1832-1847
-
17
Shmueli E, Record C O.
Adverse effects of the aminosalicylates.
Adverse Drug Reaction Bulletin.
1994;
165
623-626
-
18
Brimblecombe R.
Mesalazine. A global safety evaluation.
Scand J Gastroenterol.
1990;
25 (Suppl. 172)
66-68
-
19
Allgayer H, Ahnfelt N O, Kruis W, et al.
Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease.
Gastroenterology.
1989;
97
38-41
-
20
Pinczowski D, Ekbom A, Baron J, et al.
Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study.
Gastroenterology.
1994;
107
117-120
-
21
Moody G A, Jayanthi V, Probert C SJ, et al.
Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire.
Eur J Gastroenterol Hepatol.
1996;
8
1179-1183
-
22
Eaden J A, Abrams K, Ekbom A, et al.
Colorectal cancer prevention in ulcerative colitis: a case-control study.
Gastroenterology.
1999;
116 (Suppl.)
1739
-
23
MacGregor D J, Kim Y S, Siddiki B B, et al.
Induction of colon cancer cell apoptosis in vitro and inhibition of intestinal tumor formation in Min/+mice by balsalazide and metabolites.
Gastroenterology.
1996;
110 (Suppl.)
553
-
24
Bus P J, Nagtegaal I D, Verspaget H W, et al.
Topical administration of 5-ASA results in increased apoptosis of colorectal cancer.
Gastroenterology.
1999;
116 (Suppl.)
1680
-
25
MacGregor D J, Kim Y S, Sleisenger M E, Johnson L K.
Inhibition of colon cancer cell proliferation in vitro and azoxymethane-induced aberrant crypt formation in vivo by balsalazide and metabolites.
Gastroenterology.
1995;
108 (Suppl.)
500
-
26
Marnett L J.
Aspirin and the potential role of prostaglandins in colon cancer.
Cancer Res.
1992;
52
5575-5589
-
27
Smith B J, Curtis J F, Eling T E.
Bioactivation of xenobiotics by prostaglandin H synthetase.
Chem Biol Interact.
1991;
79
245-264
-
28
Tsujii M, Kawano S, Tsujii S, et al.
Cyclooxygenase regulates angiogenesis induced by colon cancer cells.
Cell.
1998;
93
705-716
-
29
Sano H, Kawahito Y, Wilder R L, et al.
Expression of cyclooxygenase-1 and -2 in human colorectal cancer.
Cancer Res.
1995;
55
3785-3789
-
30
Eberhart C E, Coffey R J, Radhika A, et al.
Upregulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas.
Gastroenterology.
1994;
107
1183-1188
-
31
Partik G, Kahl-Rainer P, Sedivy R, et al.
Apoptosis in human colorectal tumours: ultrastructure and quantitative studies on tissue localization and association with bak expression.
Virchows Arch.
1998;
432
415-426
-
32
Tsujitani S, Shirai H, Tatebe S, et al.
Apoptotic cell death and its relationship to carcinogenesis in colorectal carcinoma.
Cancer.
1996;
77
1711-1716
-
33
Bedi A, Pasricha P J, Akhtar A J, et al.
Inhibition of apoptosis during development of colorectal cancer.
Cancer Res.
1995;
55
1811-1816
-
34
Moss S F, Scholes J V, Holt P R.
Abnormalities of epithelial apoptosis in multistep colorectal neoplasia demonstrated by terminal deoxyuridine nick end labeling.
Dig Dis Sci.
1996;
41
2238-2247
-
35
Langman M, Boyle P.
Chemoprevention of colorectal cancer.
Gut.
1998;
43
578-585
-
36
Qiao L, Hanif R, Sphicas E, et al.
Effect of aspirin on induction of apoptosis in HT-29 human colon adenocarcinoma cells.
Biochem Pharmacol.
1998;
55
53-64
-
37
Piazza G A, Rahm A LK, Krutzsch M, et al.
Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis.
Cancer Res.
1995;
55
3110-3116
-
38
Elder D JE, Hague A, Hicks D J, Paraskeva C.
Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma cell lines.
Cancer Res.
1996;
56
2273-2276
-
39
Giardina C, Boulares H, Inan M S.
NSAIDs and butyrate sensitize a human colorectal cancer cell line to TNF-alpha and Fas ligation: the role of reactive oxygen species.
Biochim Biophys Acta.
1999;
1448
425-438
-
40
Erickson B A, Longo W E, Panesar N, et al.
The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis.
J Surg Res.
1999;
81
101-107
-
41
Picariello L, Brandi M L, Formigli L, et al.
Apoptosis induced by sulindac sulfide in epithelial and mesenchymal cells from human abdominal neoplasms.
Eur J Pharmacol.
1998;
360
105-112
-
42
Pasricha P J, Bedi A, O'Connor K, et al.
The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis.
Gastroenterology.
1995;
109
994-998
-
43
Winde G, Schmid K W, Schlegel W, et al.
Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment.
Dis Colon Rectum.
1995;
38
813-830
-
44
Eide T J.
Risk of colorectal cancer in adenoma-bearing individuals within a defined population.
Int J Cancer.
1986;
38
173-176
-
45
O'Brien M J, Winawer S J, Zauber A G, et al.
The National Polyp Study. Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas.
Gastroenterology.
1990;
98
371-379
-
46
Neugut A I, Jacobson J S, Ahsan H, et al.
Incidence and recurrence rates of colorectal adenomas: a prospective study.
Gastroenterology.
1995;
108
402-408
-
47
Van Stolk R U, Beck G J, Baron J A, et al, for the Polyp Prevention Study Group.
Adenoma characteristics at first colonoscopy as predictors of adenoma recurrence and characteristics at follow-up.
Gastroenterology.
1998;
115
13-18
-
48
Gavrieli Y, Sherman Y, Ben-Sasson S A.
Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.
J Cell Biol.
1992;
119
493-501
-
49
Sträter J, Koretz K, Günthert A R, Möller P.
In situ detection of enterocytic apoptosis in normal colonic mucosa and in familial adenomatous polyposis.
Gut.
1995;
37
819-825
-
50
Frisch S M, Francis H.
Disruption of epithelial cell-matrix interaction induces apoptosis.
J Cell Biol.
1994;
124
619-626
-
51
Liu L U, Holt P R, Krivosheyev V, Moss S F.
Human right and left colon differ in epithelial cell apoptosis and in the expression of bak, a pro-apoptotic Bcl-2 homologue.
Gut.
1999;
45
45-50
-
52
Anti M, Iascone E, Morini S, et al.
Apoptosis and cell proliferation along the entire colonic mucosa in subjects at risk for colorectal cancer.
Gastroenterology.
1997;
112 (Suppl.)
533
-
53
Spagnesi M T, Tonelli F, Dolara P, et al.
Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment.
Gastroenterology.
1994;
106
362-366
-
54
Bostick R M, Fosdick L, Wood J R, et al.
Calcium and colorectal epithelial cell proliferation in sporadic adenoma patients: a randomized, double-blinded, placebo-controlled clinical trial.
J Natl Cancer Inst.
1995;
87
1307-1315
-
55
Goldberg Y, Nassif I I, Pittas A, et al.
The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alteration in tumor suppressor and cell cycle-regulatory proteins.
Oncogene.
1996;
12
893-901
-
56
Lee F D.
Importance of apoptosis in the histopathology of drug related lesions of the large intestine.
J Clin Pathol.
1993;
46
118-122
-
57
Keller J J, Offerhaus G JA, Goodman S N, et al.
Change in apoptosis in patients treated with sulindac.
Gastroenterology.
1998;
114 (Suppl.)
2550
-
58
Sandoval M, Liu X, Mannick E E, et al.
Peroxynitrite-induced apoptosis in human intestinal epithelial cells is attenuated by mesalamine.
Gastroenterology.
1997;
113
1480-1488
-
59
Shiff S J, Qioa L, Tsai L L, Rigas B.
Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells.
J Clin Invest.
1995;
96
491-503
-
60
Yang F, de Villiers W JS, McClain C J, Varilek G W.
Mesalamine modulates nuclear factor-kB/IkB-alpha in Caco-2 cells.
Gastroenterology.
1997;
112 (Suppl.)
1125
-
61
Kaiser G C, Yan F, Polk D B.
Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes.
Gastroenterology.
1999;
116
602-609
-
62
Wahl C, Liptay S, Adler G, Schmid R M.
Sulfasalazine: a potent and specific inhibitor of nuclear factor kappaB.
J Clin Invest.
1998;
101
1163-1174
M.D. W. H. Schmiegel
Dept. of Internal Medicine Medizinische Universitätsklinik Knappschaftskrankenhaus
In der Schornau 23 - 25
44892 Bochum
Germany
Phone: +49-234-299-3409
Email: wolff.schmiegel@ruhr-uni-bochum.de
